✦ LIBER ✦

Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men

✍ Scribed by Kazuki Kawabe; Masaki Yoshida; Yukio Homma; for the Silodosin Clinical Study Group

Book ID: 109052808
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 148 KB
Volume: 98
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2006.06448.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views